A Parkinson's drug later found to treat restless legs also carries unusual behavioural risks
In short: Ropinirole is taken by mouth for Parkinson's disease and restless legs syndrome. It works by activating dopamine receptors in the brain. Its use for restless legs is a well-cited example of drug repurposing, yet the same mechanism can bring unexpected compulsive behaviours, even in people with no such history.
Ropinirole is a dopamine agonist, a drug that stimulates dopamine receptors. It acts mainly on the D2, D3 and D4 receptor types, with its strongest affinity for D3, which sit largely in the brain's limbic regions. The United States approved it for medical use in 1997, and generic versions are now widely available. In 2023 it ranked as the 212th most commonly prescribed medicine in the country, with more than two million prescriptions.
The drug's effect on movement is more complicated than a simple on-off switch. In rodents, lower doses reduce movement, which is thought to reflect activation of inhibitory presynaptic autoreceptors that lower dopamine release. Higher doses increase movement, thought to come from stimulating postsynaptic receptors. In the body, the liver enzyme CYP1A2 breaks the drug down mainly into two metabolites. One of them, 7-hydroxyropinirole, is highly potent in laboratory tests, yet it accounts for under five percent of the dose in humans.
Side effects deserve careful attention. Common ones include sleepiness, vomiting and dizziness. Serious ones may include hallucinations, a drop in blood pressure on standing, and sudden daytime sleep attacks. Dopamine agonists of the D3 type, including ropinirole and pramipexole, are also linked with hypersexuality, punding and compulsive gambling, sometimes in people with no earlier history of these behaviours. In restless legs syndrome, long-term use can lead to augmentation, where symptoms grow worse over time, and stopping can bring painful withdrawal, so the process should be supervised by a clinician.
The evidence has limits. A 2008 meta-analysis found ropinirole less effective than pramipexole for restless legs syndrome. Its safety in pregnancy and breastfeeding is described as unclear. In November 2012 a French appeals court ordered GlaxoSmithKline to pay damages to a man who had developed hypersexual behaviour and excessive gambling while taking the drug, a pattern characteristic of dopamine dysregulation syndrome.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Ropinirole
To cite this card, link to https://intellectplus.co.uk/app/health-ropinirole.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Medicine · More in Health · Latest · A–Z · All topics